Vivani Medical, Inc. (VANI)
| Market Cap | 69.90M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -23.46M |
| Shares Out | 59.23M |
| EPS (ttm) | -0.44 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 232,440 |
| Open | 1.180 |
| Previous Close | 1.180 |
| Day's Range | 1.140 - 1.220 |
| 52-Week Range | 0.960 - 7.800 |
| Beta | 3.43 |
| Analysts | Strong Buy |
| Price Target | 3.00 (+154.24%) |
| Earnings Date | Nov 13, 2024 |
About VANI
Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an e... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for VANI stock is "Strong Buy" and the 12-month stock price forecast is $3.0.
News
Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing novel, ultra long-acting drug implants, today anno...
Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West Coast
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, ann...
Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-acting drug implants, today reported financ...
Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, ann...
Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, ultra long-acting drug implants, today ann...
Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, ann...
Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing miniature, ultra long-acting, subdermal drug impla...
Vivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing miniature, ultra long-acting, subdermal drug impla...
Vivani Medical Provides Business Update and Reports Second Quarter 2024 Financial Results
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-acting drug implants, today reported financ...
Vivani Medical Provides Update on Clinical Development Plans for Miniature, Long-term, GLP-1 Obesity Implant Program, NPM-115
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, long-term drug implants, today announced t...
Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, long-term drug implants, today announced t...
Vivani Medical Announces Publication of Positive Weight Loss Data Supporting Potential Veterinary Use of OKV-119 Miniature, Long-term GLP-1 Implant
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset...
Vivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset...
Vivani Medical to Present at TIDES Conference 2024
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset...
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset...
Vivani Medical Appoints Daniel Bradbury to its Board of Directors
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants,...
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants,...
Vivani Medical (VANI) stock price surged: is it a good buy?
Vivani Medical (NASDAQ: VANI) stock price surged hard this week after the company published positive results of its ongoing weight loss drug trial. The shares surged from about $1 and reached a high o...
Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants,...
Vivani Medical Provides Business Update and Reports Third Quarter Financial Results
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants,...
Vivani Medical to Present at BIO Investor Forum
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, preclinical-stage biopharmaceutical company that develops novel, long-term drug implan...
Vivani Medical to Present at the Boulder Peptide Symposium
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, preclinical-stage biopharmaceutical company that develops novel, long-term drug implan...
Vivani Medical Subsidiary Cortigent to Present Orion Clinical Study Results at The Eye and The Chip World Research Congress on Artificial Vision October 8-10
EMERYVILLE, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants, announced today that its...
Vivani Medical Reports Second Quarter Financial Results and Provides Business Update
EMERYVILLE, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implan...
Vivani Medical, Inc. Subsidiary Cortigent Reports 5-Year Early Feasibility Study Update for the Orion® Visual Cortical Prosthesis System
EMERYVILLE, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI), an innovative, near-clinical stage biopharmaceutical company that is developing novel, miniature, long-term therapeutic implan...